このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Matinas BioPharma Holdings 将来の成長

Future 基準チェック /06

Matinas BioPharma Holdingsは、47.9%と89.1%でそれぞれ年率47.9%で利益と収益が成長すると予測される一方、EPSはgrowで49.4%年率。

主要情報

47.9%

収益成長率

49.4%

EPS成長率

Biotechs 収益成長	27.9%
収益成長率	89.1%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	15 Aug 2024

今後の成長に関する最新情報

Recent updates

Here's Why We're Not Too Worried About Matinas BioPharma Holdings' (NYSEMKT:MTNB) Cash Burn Situation

Feb 23

業績と収益の成長予測

NYSEAM:MTNB - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	N/A	-36	N/A	N/A	2
12/31/2025	N/A	-34	N/A	N/A	2
12/31/2024	N/A	-24	N/A	N/A	2
6/30/2024	N/A	-23	-18	-18	N/A
3/31/2024	N/A	-23	-17	-17	N/A
12/31/2023	1	-23	-15	-15	N/A
9/30/2023	2	-21	-15	-15	N/A
6/30/2023	3	-21	-16	-16	N/A
3/31/2023	4	-21	-19	-18	N/A
12/31/2022	3	-21	-20	-19	N/A
9/30/2022	2	-24	-20	-19	N/A
6/30/2022	1	-25	-20	-20	N/A
3/31/2022	0	-24	-16	-15	N/A
12/31/2021	0	-24	-15	-15	N/A
9/30/2021	0	-24	-16	-16	N/A
6/30/2021	0	-22	-15	-15	N/A
3/31/2021	0	-23	-17	-17	N/A
12/31/2020	0	-23	-17	-17	N/A
9/30/2020	0	-22	-18	-18	N/A
6/30/2020	N/A	-21	-17	-17	N/A
3/31/2020	0	-19	-16	-16	N/A
12/31/2019	0	-18	-14	-14	N/A
9/30/2019	0	-16	-12	-12	N/A
6/30/2019	0	-15	-11	-10	N/A
3/31/2019	0	-15	-11	-11	N/A
12/31/2018	0	-15	-11	-10	N/A
9/30/2018	0	-15	-10	-10	N/A
6/30/2018	0	-15	-10	-10	N/A
3/31/2018	0	-16	N/A	-11	N/A
12/31/2017	0	-33	N/A	-11	N/A
9/30/2017	0	-31	N/A	-12	N/A
6/30/2017	0	-34	N/A	-10	N/A
3/31/2017	0	-31	N/A	-8	N/A
12/31/2016	N/A	-12	N/A	-6	N/A
9/30/2016	N/A	-12	N/A	-5	N/A
6/30/2016	0	-8	N/A	-6	N/A
3/31/2016	0	-9	N/A	-7	N/A
12/31/2015	0	-9	N/A	-8	N/A
9/30/2015	0	-10	N/A	-9	N/A
6/30/2015	0	-11	N/A	-9	N/A
3/31/2015	0	-11	N/A	-8	N/A
12/31/2014	N/A	-10	N/A	-8	N/A
9/30/2014	N/A	-9	N/A	-7	N/A
6/30/2014	N/A	-8	N/A	-6	N/A
3/31/2014	N/A	-6	N/A	-5	N/A

アナリストによる今後の成長予測

収入対貯蓄率: MTNB今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: MTNB今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: MTNB今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: MTNB来年は収益がないと予測されています。

高い収益成長: MTNB来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: MTNBの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Matinas BioPharma Holdings 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

No longer forecast to breakeven

Consensus revenue estimates fall by 90%

Consensus revenue estimates fall by 46%

Forecast to breakeven in 2025

Price target decreased to US$2.75

Consensus forecasts updated

Recent updates

New minor risk - Share price stability

Matinas BioPharma Holdings, Inc. to Report Q2, 2024 Results on Aug 14, 2024

Matinas Biopharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in Its Oral Mat2203 Compassionate/Expanded Use Access Program

New major risk - Revenue and earnings growth

Matinas BioPharma Holdings, Inc. to Report Q1, 2024 Results on May 09, 2024

New minor risk - Shareholder dilution

Matinas BioPharma Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

New major risk - Share price stability

Matinas BioPharma Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Matinas Biopharma Announces Positive in Vivo Safety Data with Its Oral Lnc-Docetaxel Formulation

Matinas BioPharma Holdings, Inc. to Report Fiscal Year 2023 Results on Mar 27, 2024

Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards

Matinas Biopharma Provides Positive Outcomes Update on the Mat2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution

Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis

Matinas BioPharma Holdings, Inc. Demonstrates in Vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides

Matinas Biopharma Holdings, Inc. Provides Update to Mat2203 Regulatory and Development Pathway Following Feedback from FDA

Third quarter 2023 earnings released: US$0.028 loss per share (vs US$0.025 loss in 3Q 2022)

Matinas Biopharma Holdings, Inc. Announces Positive in vivo Efficacy Results of Oral LNC Docetaxel Formulation in a Melanoma Model

Matinas BioPharma Holdings, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Matinas BioPharma Holdings, Inc. Announces Complete Clinical Resolution of a Patient’s Recurrent Hemorrhagic Cystitis Due to Candida krusei Following Treatment with MAT2203

No longer forecast to breakeven

Insufficient new directors

Matinas Biopharma Holdings Receives Non-Compliance Notice From NYSE American LLC

Matinas Biopharma Holdings Receives Non-Compliance Notice From NYSE American LLC

Matinas BioPharma Holdings, Inc., Annual General Meeting, Nov 01, 2023

Matinas BioPharma Announces Publication of Results from the Phase 2 EnACT Clinical Trial of Mat2203 in the IDSA Journal Clinical Infectious Diseases

Matinas BioPharma Holdings, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Consensus revenue estimates fall by 90%

Matinas BioPharma Holdings, Inc. to Report Q1, 2023 Results on May 10, 2023

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates fall by 46%

Forecast to breakeven in 2025

Price target decreased to US$2.75

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Matinas BioPharma Holdings, Inc. Announces Positive Interim Data from the Phase 2 EnACT Trial of MAT2203 for the Treatment of Cryptococcal Meningitis, Exceeding Primary Endpoint Threshold, Patient Survival in All-Oral Cohort 4 Regimen Currently 90%

Matinas BioPharma Holdings, Inc., Annual General Meeting, Nov 14, 2022

Matinas BioPharma Holdings, Inc. Announces Board Changes, Effective October 1, 2022

Consensus forecasts updated

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 41,381%

Price target decreased to US$2.75

Insufficient new directors

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues miss analyst expectations

No longer forecast to breakeven

Insufficient new directors

Forecast to breakeven in 2024

Matinas Biopharma Announces Unanimous Dsmb Approval to Progress into Fourth and Final Cohort of Patients in the Enact Trial of Mat2203 for the Treatment of Cryptococcal Meningitis

Matinas Biopharma Announces Positive Data in the Ongoing Enact Trial of Mat2203 for the Treatment of Cryptococcal Meningitis, Exceeding the Prespecified Primary Endpoint Threshold

Consensus forecasts updated

Consensus revenue estimates increase to US$2.48m

Forecast to breakeven in 2025

Consensus revenue estimates increase to US$1.27m

Full year 2020 earnings released: US$0.12 loss per share (vs US$0.13 loss in FY 2019)

Price target decreased to US$3.08

Here's Why We're Not Too Worried About Matinas BioPharma Holdings' (NYSEMKT:MTNB) Cash Burn Situation

Matinas BioPharma Announces Topline Results from ENHANCE-IT Study of LYPDISO™ Against Vascepa®

Price target raised to US$3.75

Matinas BioPharma Holdings, Inc. Announces FDA Conditional Acceptance of LYPDISO™ as the Brand Name for MAT9001

New 90-day high: US$1.47

Matinas Biopharma Holdings, Inc. Announces Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate Oral Formulations of Gilead’s Antiviral Remdesivir Utilizing Matinas LNC Platform Delivery Technology

Matinas BioPharma Holdings, Inc. Appoints Hui Liu as Chief Technology Officer

New 90-day high: US$0.90

Matinas BioPharma Holdings, Inc. Awards Up to $3.75 Million from the Cystic Fibrosis Foundation to Support Development of Oral Amikacin (MAT2501) for the Treatment of NTM Infections in Cystic Fibrosis Patients

Analysts increase revenue estimates to US$1.37m

Revenue beats expectations, earnings disappoint

Matinas BioPharma Announces Unanimous DSMB Approval to Progress into Second Cohort of Patients in the EnACT Study of MAT2203 (Oral Amphotericin B) for the Treatment of Cryptococcal Meningitis